Roberta L. Buell is a Principal at onPoint Oncology Inc., specializing in oncology reimbursement. With over 23 years of experience in billing, coding, and drug therapy reimbursement, she's a nationally recognized expert and frequent speaker on regulatory and reimbursement issues. Bobbi has led more than 600 seminars since 1991 and currently serves as content director for focalPoint® and assistPoint®. Learn more about Bobbi here .
UnitedHealthcare Medicare Advantage shows highest drug denial rates in 2024–2025. Delays, AI denials, and DOJ scrutiny raise concerns for providers.
Preview the 2026 ICD-10-CM code updates: 500+ proposed changes across specialties, from diabetes and cancer to cannabis hyperemesis and Gulf War illness.
CMS finalizes 2026 Medicare Advantage and Part D rule: no AI limits or obesity drug coverage, but IRA updates, D-SNP changes, and a 5.06% payment increase remain.
CMS proposes 2.4% hospital pay increase for FY 2026, updates to quality programs, and ends equity measures. Read key IPPS rule changes and hospital impacts.
No articles match your search.
The Comparative Report puts ASP, the Medicare payment limit, WAC and AWP for up to 15 drugs on one timeline. Ten-plus years of monthly history, per HCPCS unit.
Included with BuyandBill Pro for $37/month billed annually.
Trastuzumab class, seven products
Actual published ASP, Jan 2015 to Aug 2026.
